许多针对SARS-CoV-2的羟氯喹试验存在冗余且可能不符合伦理:基于NIH临床试验注册库的分析
该研究检索了2020年2月至11月间在NIH临床试验注册库登记的针对SARS-CoV-2的羟氯喹试验,共识别出206项研究。截至2020年11月,135项正在进行,22项已完成,46项暂停或终止;暂停或终止原因包括患者招募困难(n=9)、新证据显示羟氯喹无获益(n=7)及监管委员会建议终止(n=10)。作者认为医学界对羟氯喹的政治关注响应迅速,而对不断更新的无效证据响应缓慢。
要点
- 2020年2月至11月,NIH临床试验注册库共登记206项针对SARS-CoV-2的羟氯喹研究。
- 截至2020年11月,135项研究正在进行,22项已完成,46项暂停或终止。
- 暂停或终止原因包括招募困难(n=9)、证据显示无获益(n=7)和监管建议终止(n=10)。
核心结论
- 疫情期间最初数月启动了大量羟氯喹临床试验,截至2020年11月仍有相当比例的研究在进行。
- 医学界对羟氯喹的政治关注响应非常迅速,而对不断更新的无效医学证据响应缓慢得多。
研究设计与样本
- 研究识别并提取了2020年2月至11月间在公开的美国国立卫生研究院(NIH)临床试验注册库登记的、使用羟氯喹治疗SARS-CoV-2的研究数据。
主要发现
- 2020年2月至11月间,NIH临床试验注册库共登记206项研究羟氯喹用于SARS-CoV-2的试验。
- 截至2020年11月,135项研究列为正在进行,22项已完成,46项暂停或终止。
- 暂停或终止的原因包括患者招募困难(n=9)、新证据显示羟氯喹缺乏获益(n=7)以及监管委员会建议终止(n=10)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to map the landscape of trials investigating hydroxychloroquine (HCQ) for SARS-CoV-2 in order to draw conclusions about how clinical trials have been conducted in the pandemic environment and offer potential regulatory recommendations. STUDY DESIGN AND SETTING: We identified and captured data related to registered studies using HCQ to treat SARS-CoV-2 registered with the publicly available National Institutes of Health (NIH) Clinical Trials Registry between February and November 2020. RESULTS: Between February and November 2020, 206 studies investigating HCQ in SARS-CoV-2 were registered with the NIH Clinical Trials Registry. As of November 2020, 135 studies were listed as ongoing, 22 have been completed, and 46 are either suspended or have been terminated. Reasons for suspension or termination included difficulties with patient recruitment (n = 9), emerging evidence showing a lack of benefit of HCQ (n = 7), and recommendations by regulatory boards to discontinue (n = 10). CONCLUSION: Many clinical trials of HCQ were launched in the first months of the pandemic, and a significant proportion of them remained active as of November 2020. The medical community appears to have responded very quickly to political interest in HCQ, while responding much more slowly to the evolving medical evidence of its lack of efficacy.
引用
- Yogendrakumar V, Dewar B, McGuinty M, et al. Many trials of hydroxychloroquine for SARS-CoV-2 were redundant and potentially unethical: an analysis of the NIH clinical trials registry. J Clin Epidemiol. 2021. PMID: 34780978. doi:10.1016/j.jclinepi.2021.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。